[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 437,425
  • Shares Outstanding, K 51,644
  • Annual Sales, $ 742,900 K
  • Annual Income, $ 52,600 K
  • EBIT $ 177 M
  • EBITDA $ 283 M
  • 60-Month Beta 2.33
  • Price/Sales 0.57
  • Price/Cash Flow 2.25
  • Price/Book 0.83

Options Overview Details

View History
  • Implied Volatility 74.80% (-23.40%)
  • Historical Volatility 47.16%
  • IV Percentile 27%
  • IV Rank 8.11%
  • IV High 348.73% on 03/18/26
  • IV Low 50.62% on 01/16/26
  • Expected Move (DTE 12) 0.84 (9.94%)
  • Put/Call Vol Ratio 1.10
  • Today's Volume 734
  • Volume Avg (30-Day) 339
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 12,176
  • Open Int (30-Day) 10,642
  • Expected Range 7.63 to 9.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 1
  • High Estimate $-0.25
  • Low Estimate $-0.25
  • Prior Year $0.71
  • Growth Rate Est. (year over year) -135.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.53 +12.46%
on 05/01/26
9.32 -9.12%
on 05/01/26
+0.09 (+1.07%)
since 04/01/26
3-Month
7.53 +12.46%
on 05/01/26
11.96 -29.18%
on 02/03/26
-2.87 (-25.31%)
since 01/30/26
52-Week
4.71 +79.83%
on 05/06/25
14.06 -39.76%
on 01/07/26
+3.55 (+72.15%)
since 05/01/25

Most Recent Stories

More News
Emergent Biosolutions: Q1 Earnings Snapshot

Emergent Biosolutions: Q1 Earnings Snapshot

EBS : 8.47 (+2.92%)
Emergent BioSolutions Reports First Quarter 2026 Financial Results

First Quarter 2026 Total Revenues of $156.1 million First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin...

EBS : 8.47 (+2.92%)
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for...

EBS : 8.47 (+2.92%)
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a multi-year agreement with SAB Biotherapeutics, Inc. (Nasdaq: SABS , SAB BIO) to support...

EBS : 8.47 (+2.92%)
SABS : 3.47 (-7.22%)
Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives

Star left fielder joins forces with Emergent to educate the public on the importance of being prepared with NARCAN ® Nasal Spray Schneider shares his family’s story as part of Emergent’s Opioid...

EBS : 8.47 (+2.92%)
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States

Emergent’s Canton facility will manufacture drug substance and obtains exclusive distribution rights GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc....

EBS : 8.47 (+2.92%)
Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company has closed on a new credit facility agreement with OrbiMed for a new $150...

EBS : 8.47 (+2.92%)
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial...

EBS : 8.47 (+2.92%)
Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN...

EBS : 8.47 (+2.92%)
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a series of initiatives designed to help increase access to NARCAN ® Nasal Spray and encourage...

EBS : 8.47 (+2.92%)

Business Summary

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside...

See More

Key Turning Points

3rd Resistance Point 11.14
2nd Resistance Point 10.23
1st Resistance Point 9.35
Last Price 8.47
1st Support Level 7.56
2nd Support Level 6.65
3rd Support Level 5.77

See More

52-Week High 14.06
Fibonacci 61.8% 10.49
Fibonacci 50% 9.39
Last Price 8.47
Fibonacci 38.2% 8.28
52-Week Low 4.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.